First-Line Treatment of Waldenström’s Macroglobulinaemia:Considerations Based on the Dutch National Guideline
Waldenström macroglobulinemia (WM) is a rare B-cell Non-Hodgkin Lymphoma. There are only few prospective randomized clinical trials to guide treatment recommendations and there is no international consensus on a preferred first line treatment approach. In the recently revised Dutch guideline for WM, we describe recommendations for practice based as much as possible on the known data. Here, we summarize the considerations for first-line treatment based on these Dutch guidelines. Available evidence is summarized, including efficacy and toxicity data. Combinations of Rituximab with chemotherapy,... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Reihe/Periodikum: | Amaador , K , Kersten , M J , Visser , H P J , Nieuwenhuizen , L , Schop , R F J , Chamuleau , M E D , Velders , G A , Minnema , M C & Vos , J M I 2022 , ' First-Line Treatment of Waldenström’s Macroglobulinaemia : Considerations Based on the Dutch National Guideline ' , Hemato , vol. 3 , no. 4 , pp. 704-717 . https://doi.org/10.3390/hemato3040047 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26687688 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://research.vumc.nl/en/publications/3bc8ba22-5a0f-400a-9357-7c87028b25a7 |